Ind-Swift Labs to sell API and CRAMS business to Synthimed for Rs 1,650cr
In a groundbreaking move that has left the pharmaceutical sector buzzing, the Board of Directors of Ind-Swift Laboratories Limited (“Ind-Swift”) announced the blockbuster sale of its active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) divisions to Synthimed Labs Private Limited (“Synthimed”) on September 6, 2023. The mega-deal, valued at a whopping INR […]